Samplix Secures €25M for Antibody Discovery

A biotechnology funding headline can look much larger than the new cash entering the company. Samplix's latest financing is a useful example of why the structure matters.

What happened

Danish life-sciences tools company Samplix announced a €25 million first closing led by WLanholding, with participation from existing shareholders. The total comprises €3 million in new capital and €22 million from the conversion of existing shareholder convertible bonds into equity. The broader round remains open with a €30 million target.

Samplix develops Xdrop, a droplet-microfluidics platform that isolates and screens individual cells based on function. In antibody discovery, it can help researchers identify cells producing antibodies with desired properties and recover them for further analysis.

The company intends to use the financing to support the commercial expansion of its platform and strengthen its financial position. Converting debt-like instruments improves the balance sheet but does not provide €22 million of new operating cash.

Why it matters

Finding antibodies with useful biological activity is technically demanding. Functional single-cell screening may help researchers select promising candidates faster than workflows requiring repeated conventional screening.

Commercialising laboratory instruments still depends on customer adoption, technical reliability and recurring demand. The financing structure highlights how specialist biotech tools businesses may need balance-sheet support as well as fresh investment.

The bigger picture

Life-sciences funding announcements require careful distinction between equity, debt and conversions. The Samplix transaction brings useful resources and a cleaner capital structure, but the actual new-money component is only €3 million.